GDTC logo

CYTOMED THERAPEUTICS LTD

GDTCNASDAQ
🏆 #4883 by market capUS Equity
$0.87▼ $0.01 (−1.13%)
Market closed · at close
🔔
Track GDTC
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.1%
7d▲ 1.6%
14d▲ 1.1%
30d▼ 4.1%
ytd▼ 35.8%
1y▼ 61.2%
🏦Market Cap
$10M
Small Cap
📈Revenue Growth (YoY)
44.5%
High Growth
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
43.1x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.87 – $0.87
52-Week Range
—
Volume (shares)
200
Avg Volume (shares)
—
Shares Outstanding
11.9M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$324,387
Last Q Revenue
$157,289
P/E Ratio
—
P/S Ratio
43.1x
EPS (TTM)
—
Dividend Yield
—
Dilution (1yr)
+2.2%
GDTC logo

CYTOMED THERAPEUTICS LTD

GDTC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$319K▲ +359.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-277.7%▼ −468.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$5M▲ +44.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$4M▲ +7.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
11.8M▲ +2.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2M▼ −$3M YoY
StockOtter · stockotter.space

About CYTOMED THERAPEUTICS LTD

CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Jul 2025

Latest News & Updates

News unavailable.